Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-20.33 Insider Own0.10% Shs Outstand331.40M Perf Week-2.13%
Market Cap53.88B Forward P/E9.83 EPS next Y16.54 Insider Trans-11.95% Shs Float329.49M Perf Month2.05%
Income-6801.00M PEG- EPS next Q3.39 Inst Own91.80% Short Float3.19% Perf Quarter-4.12%
Sales15.94B P/S3.38 EPS this Y-543.10% Inst Trans6.87% Short Ratio3.12 Perf Half Y-22.58%
Book/sh207.88 P/B0.78 EPS next Y6.09% ROA-3.60% Target Price215.95 Perf Year-30.52%
Cash/sh19.46 P/C8.35 EPS next 5Y7.40% ROE-6.40% 52W Range142.81 - 256.80 Perf YTD-0.61%
Dividend2.88 P/FCF12.51 EPS past 5Y15.01% ROI-2.10% 52W High-36.69% Beta1.28
Dividend %1.77% Quick Ratio1.10 Sales past 5Y21.90% Gross Margin86.40% 52W Low13.84% ATR4.65
Employees17800 Current Ratio1.20 Sales Q/Q12.00% Oper. Margin-37.50% RSI (14)47.77 Volatility2.38% 2.86%
OptionableYes Debt/Eq0.44 EPS Q/Q714.40% Profit Margin-27.60% Rel Volume0.76 Prev Close163.70
ShortableYes LT Debt/Eq0.38 EarningsFeb 06 BMO Payout- Avg Volume3.36M Price162.58
Recom2.10 SMA202.43% SMA50-3.23% SMA200-18.17% Volume2,566,887 Change-0.68%
Feb-23-18Initiated SunTrust Buy $200
Feb-07-18Reiterated Leerink Partners Outperform $237 → $242
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-27-17Resumed Leerink Partners Outperform $237
Nov-02-17Reiterated RBC Capital Mkts Outperform $250 → $221
Oct-19-17Reiterated RBC Capital Mkts Outperform $277 → $250
Oct-17-17Reiterated UBS Buy $275 → $255
Oct-02-17Reiterated Barclays Equal Weight
Sep-25-17Reiterated RBC Capital Mkts Outperform $285 → $277
Sep-20-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Neutral $231
Jun-09-17Reiterated Mizuho Buy $275 → $267
May-10-17Reiterated RBC Capital Mkts Outperform $279 → $284
May-10-17Downgrade Goldman Buy → Neutral
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Mar-22-18 09:00AM  Allergan's Battered Shares Are Poised To Rise Over 35% Investopedia
Mar-21-18 07:00PM  Ozurdex(R) (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion PR Newswire
Mar-18-18 03:00PM  Barron's Picks And Pans: Allergan, Broadcom, Gap And More Benzinga
Mar-17-18 12:01AM  [$$] Allergan's Stock Is Headed for a Face-Lift
Mar-15-18 10:13AM  Mylan N.V. Stock Is Headed Back Down to $40 InvestorPlace
09:05AM  Allergan Considering All Strategic Options 'With A Sense Of Urgency' Benzinga
07:35AM  Allergan CEO: We Are Looking at All Options to Create Shareholder Value
Mar-14-18 01:57PM  Stocks are selling off today on the huge Retail Sales miss: NYSE trader Yahoo Finance Video
08:29AM  The Zacks Analyst Blog Highlights: Lockheed Martin, Allergan, Barclays, Constellation Brands and Southwest Airlines Zacks
Mar-13-18 06:05PM  Allergan CEO Brent Saunders Got $32.8 Million Pay Package for 2017 Bloomberg
04:15PM  Top Analyst Reports for Lockheed Martin, Allergan & Barclays Zacks
Mar-08-18 10:31AM  Why Is Allergan (AGN) Down 10.1% Since its Last Earnings Report? Zacks
12:15AM  [$$] Challenges to Botox threaten a market makeover Financial Times
Mar-06-18 12:54PM  These Are Billionaire Paul Singers Stock Picks That You NEED to Avoid Insider Monkey
09:00AM  CoolSculpting® Takes to the Ice with Iconic Figure Skater Johnny Weir to Debunk Fat Loss Myths PR Newswire
Mar-05-18 03:30PM  Goldman Sachs Sees 100% Upside In This Biopharma Company Benzinga
Mar-04-18 12:37PM  Mylan shares bounce on plans for Botox copycat, 2018 drug launches MarketWatch
11:33AM  Here's Why Allergan plc Stock Tanked 14.4% in February Motley Fool
Mar-02-18 11:55AM  Mylan shares bounce on plans for Botox copycat, 2018 drug launches MarketWatch
09:50AM  You still cant buy this EpiPen competitor, eight months later MarketWatch
Mar-01-18 05:30PM  Pressure May Be On Allergan to Strike a Major Deal, As Botox Gets Another Rival
05:06PM  Allergan Tanks To 5-Year Low As Botox Rivalry Heats With Mylan Investor's Business Daily
10:16AM  Mylan Shares Jump After Earnings Beat
08:56AM  Mylans Plan to Copycat Botox Creates a Familiar Wrinkle for Allergan Bloomberg
Feb-28-18 05:36PM  Mylan teams up with Revance on biosimilar for Botox Reuters
04:30PM  Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018 PR Newswire
04:20PM  Allergan to Present at The Barclays Global Healthcare Conference PR Newswire
11:19AM  How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Say It Can't Be Good Forbes
Feb-27-18 06:00PM  U.S. to seek reimbursement from opioid makers, distributors Reuters
05:59PM  DOJ to support lawsuits against companies selling opioids Associated Press
Feb-26-18 07:15PM  Allergan Handed Patent Defeat Over Restasis
06:59PM  Cramer's lightning round: My biggest worry about Allergan CNBC Videos
06:50PM  Cramer's lightning round: My biggest worry about Allergan CNBC
04:15PM  Allergan to Present at The Cowen and Company 38th Annual Health Care Conference PR Newswire
12:46PM  [$$] Board Denies Indian Tribe's Push to End Challenge of Restasis Patents The Wall Street Journal
10:59AM  U.S. patent court deals setback to Allergan's Restasis strategy Reuters
10:16AM  Allergan denied dismissal of patent challenges for dry eye medication Restasis MarketWatch
10:03AM  Warren Buffett Re-Hedged His Bet Bloomberg
08:36AM  Allergan denied dismissal of patent challenges for dry eye medication Restasis by U.S. patent board MarketWatch
Feb-25-18 05:01PM  Benzinga's Insider Buys Of The Week: Allergan, HCA, Opko And More Benzinga
Feb-22-18 05:31PM  Larry Robbins' Top 5 New Buys in 4th Quarter
02:19PM  Mason Hawkins' Southeastern Bets Big on CenturyLink
08:00AM  FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg PR Newswire
Feb-21-18 02:38PM  Should You Follow Seth Klarman and David Tepper Into Allergan?
Feb-16-18 07:01PM  Jim Cramer: Drug Stocks on the Move
06:58PM  Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego PR Newswire
05:48PM  Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2017
03:31PM  United Therapeutics reaches patent settlement with Actavis American City Business Journals
03:16PM  United Therapeutics settles patent litigation over $157M drug American City Business Journals
08:44AM  Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up Zacks
06:04AM  Why in the World Does Warren Buffett Like Teva Pharmaceutical? Motley Fool
Feb-15-18 07:47PM  Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'
Feb-14-18 08:02AM  How Confident Are Insiders About Allergan And More? Simply Wall St.
Feb-13-18 06:22PM  Jerome Dodson Comments on Allergan
06:14PM  Jerome Dodson's Parnassus Fund 4th Quarter Commentary
Feb-11-18 11:57PM  [$$] New Tax Law Haunts Companies That Did Inversion Deals The Wall Street Journal
09:54AM  Stocks That Fell to 3-Year Lows in the Week of Feb. 9
07:00AM  New Tax Law Haunts Companies That Did Inversion Deals The Wall Street Journal
Feb-10-18 05:36PM  OxyContin maker will stop promoting opioids to doctors Associated Press
Feb-09-18 09:50AM  Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View Zacks
08:00AM  Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates PR Newswire
Feb-08-18 09:41AM  The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease Benzinga
04:36AM  Array BioPharma and Allergan Just Scored Big On Phase III Data Market Exclusive
Feb-06-18 05:30PM  Allergan Pops On Consensus-Topping Quarter, Strong Migraine Trial Investor's Business Daily
04:48PM  Centene, LabCorp Among Healthcare Stock Gainers
04:19PM  Dow Finishes With Gain of 567 Points; S&P 500 and Nasdaq Also Close Higher
12:20PM  Allergan CEO: We Are Staying in Ireland
12:16PM  Lululemon CEO resigns, GM up on earnings, and Allergan's forecast disappoints Yahoo Finance
11:59AM  Lulu CEO departs, GM up after earnings, Allergan's forecast disappoints Yahoo Finance Video
11:20AM  Charts of the Day: Lululemon, GM, Allergan Yahoo Finance Video
10:30AM  Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales Zacks
10:24AM  Allergan's profit beats; migraine drug succeeds in key study Reuters
10:22AM  Stocks to Watch: Boeing, Netflix, GM, Lululemon, Micron, Skyworks, Pfizer, ADM The Wall Street Journal
08:50AM  Allergan's profit beats; migraine drug succeeds in key study Reuters
08:40AM  Allergan (AGN) Beats Q4 Earnings & Sales, Stock Up Zacks
08:19AM  A Regular Winning Trade Becomes Roadkill in Market Meltdown
07:28AM  Allergan shares rise after Q4 profit, revenue beats MarketWatch
07:06AM  Allergan shares surge after positive late-stage migraine drug results MarketWatch
07:02AM  Allergan smashes earnings estimates, says a trial for its migraine drug succeeds CNBC
07:00AM  Allergan Reports Solid Finish to 2017 with 12% Increase in Fourth Quarter GAAP Net Revenues to $4.3 Billion PR Newswire
06:50AM  Allergan plc to Host Earnings Call ACCESSWIRE
06:45AM  Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Feb-05-18 09:17AM  [$$] Allergan Names Matthew Walsh New Finance Chief The Wall Street Journal
08:03AM  Allergan names current Catalent CFO as its CFO MarketWatch
07:51AM  Matthew M. Walsh Appointed Executive Vice President and Chief Financial Officer of Allergan plc PR Newswire
07:40AM  Allergan's Pipeline Matters More Than Its Earnings Do: RBC
Feb-02-18 05:22PM  Arnold Van Den Berg Fuels Prem Watsa's Fairfax India in 4th Quarter
03:06PM  Allergan completes restructuring, pushes hard in China Reuters
01:16PM  Teva Completes Sale of Women's Health Segment for $703M Zacks
12:48PM  Teva Is Playing Debt Roulette and It May Just Work
10:42AM  Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod Zacks
Feb-01-18 04:31PM  FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia PR Newswire
04:30PM  FDA approves Allergan's Avycaz for two types of pneumonia Reuters
02:19PM  Vanguard Health Care Fund Buys Danaher, CVS Health, Adds to Allergan
10:42AM  Allergan (AGN) to Report Q4 Earnings: What's in the Cards? Zacks
08:49AM  Allergan to pay Israel's Teva Pharm $700 million to settle dispute Reuters
08:24AM  Allergan will pay Teva $700 mln to settle dispute MarketWatch
07:55AM  New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-31-18 04:15PM  Allergan to Present at The Leerink Partners 7th Annual Global Healthcare Conference PR Newswire
07:31AM  Allergan Introduces "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® and Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Golfer Ian Poulter PR Newswire
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hilado Maria TeresaExecutive Vice PresidentMar 15Buy167.39895149,81426,530Mar 19 09:36 AM
WALSH MATTHEW MEVP, Chief Financial OfficerMar 08Buy153.961,000153,96025,416Mar 08 10:44 AM
SAUNDERS BRENT LChairman, President and CEOMar 08Buy152.533,300503,349180,931Mar 08 10:25 AM
Boccuzi Joseph HDirectorMar 05Buy143.42900129,0781,862Mar 09 04:31 PM
WALSH MATTHEW MEVP, Chief Financial OfficerFeb 21Buy160.942,000321,88024,416Feb 22 04:25 PM
Meury WilliamChief Commercial OfficerFeb 14Option Exercise63.1723,6131,491,73778,600Feb 16 05:10 PM
Meury WilliamChief Commercial OfficerFeb 14Sale160.6258,8799,457,36919,721Feb 16 05:10 PM
BODINE CHRIS WDirectorDec 07Buy164.773,030499,25317,098Dec 07 05:21 PM
SAUNDERS BRENT LChairman, President and CEODec 06Buy164.744,600757,794186,377Dec 06 12:31 PM
COUGHLIN CHRISTOPHER JDirectorDec 05Buy163.3010,0001,633,00014,446Dec 05 04:16 PM
Meury WilliamChief Commercial OfficerDec 01Option Exercise78.8811,807931,33668,828Dec 04 06:21 PM
Meury WilliamChief Commercial OfficerDec 01Sale173.8911,8072,053,11957,021Dec 04 06:21 PM
SAUNDERS BRENT LChairman, President and CEOJun 16Buy235.964410,327131,178Sep 18 08:49 PM
Basgoz NesliDirectorMay 18Option Exercise84.441,889159,5077,919May 22 04:26 PM
Basgoz NesliDirectorMay 18Sale220.451,889416,4306,030May 22 04:26 PM
GALLAGHER MICHAEL RDirectorMay 04Option Exercise245.2517,6934,339,20820,272May 05 06:34 PM
SAUNDERS BRENT LChairman, President and CEOMar 29Buy242.214310,299131,135Sep 18 08:49 PM